LOVE Stock Overview
Engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Cannara Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.75 |
| 52 Week High | CA$1.04 |
| 52 Week Low | CA$0.52 |
| Beta | 1.13 |
| 1 Month Change | 10.29% |
| 3 Month Change | 20.97% |
| 1 Year Change | -15.73% |
| 3 Year Change | -42.31% |
| 5 Year Change | -37.50% |
| Change since IPO | -75.41% |
Recent News & Updates
Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share Price
Nov 26
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Recent updates
Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share Price
Nov 26These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Jul 14Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Shareholder Returns
| LOVE | CA Personal Products | CA Market | |
|---|---|---|---|
| 7D | 4.2% | 1.5% | -2.6% |
| 1Y | -15.7% | 5.2% | 15.2% |
Return vs Industry: LOVE underperformed the Canadian Personal Products industry which returned 5% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned 15.2% over the past year.
Price Volatility
| LOVE volatility | |
|---|---|
| LOVE Average Weekly Movement | 15.0% |
| Personal Products Industry Average Movement | 10.9% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: LOVE's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: LOVE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Zohar Krivorot | cannara.ca |
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations.
Cannara Biotech Inc. Fundamentals Summary
| LOVE fundamental statistics | |
|---|---|
| Market cap | CA$67.51m |
| Earnings (TTM) | CA$6.44m |
| Revenue (TTM) | CA$81.75m |
10.5x
P/E Ratio0.8x
P/S RatioIs LOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOVE income statement (TTM) | |
|---|---|
| Revenue | CA$81.75m |
| Cost of Revenue | CA$51.96m |
| Gross Profit | CA$29.79m |
| Other Expenses | CA$23.35m |
| Earnings | CA$6.44m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.072 |
| Gross Margin | 36.44% |
| Net Profit Margin | 7.88% |
| Debt/Equity Ratio | 54.2% |
How did LOVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cannara Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|